OZ Biosciences has introduced a product line dedicated to in vivo transfection.
In vivo Magnetofection reagents have been designed for in vivo targeted transfection and infection.
This system combines magnetic nanoparticles and nucleic acid vectors that will be confined after injection at the magnetically targeted site.
“In this way, targeted delivery minimizes systemic distribution and reduces toxicity,” explained Olivier Zelphati, CEO of OZ Biosciences.
“Furthermore, the magnetic force will enhance the uptake of magnetic nanoparticles by the target tissue, and thus improve the efficiency of transfection or transduction. This allows reducing the required nucleic acid doses and the process time of delivery which is crucial for improvement of in vivo nucleic acid delivery.”
Gene vectors /nanoparticles complexes can be easily administrated through various injection routes such as systemic administration (intravenous, intra-artery) or local administration (intraperitoneal, intratumoral, intracerebroventricular, intramuscular ).
OZ Biosciences offers three types of ready-to-use In vivo Magnetofection reagents:
- Non viral applications: In vivo PolyMag, a cationic polymer-based magnetic nanoparticles formulation, and In vivo DogtorMag, a cationic lipid-based magnetic nanoparticles formulation, have been designed for in vivo targeted transfection of various types of nucleic acids such as DNA, RNA and oligonucleotides.
- Viral applications: In vivo ViroMag is an optimized nanoparticles formulation dedicated to viral vectors that allows reduction of titer virus. It is particularly suitable for Lentiviral/Retroviral, Adenoviral and Adeno-Associated Viral (AAV) vectors.
